Sector IntelligenceZurich

VALUATION DIAGNOSTIC
Biotech & Contract Research

Specific market analysis for Biotech & Contract Research companies based in Zurich.

Pro-Forma Valuation

Market demand in Zurich for Biotech & Contract Research assets remains strong.

KEY DRIVER

"Basel pharma ecosystem, highest multiples on platform, GLP/GMP regulatory moats, biologics pipeline demand."

Local Multiples (Est.)

7.0 - 10.0x Statutory

Get Your Report

Generate a certified valuation for your Biotech & Contract Research business in Zurich.

Start Valuation

Valuation Impact by Size (DACH 2025)

Size BucketMultiple RangeImpact
Micro (< CHF 1M EBITDA)4.3x - 5.8x-33.3%
Small (CHF 1M - 2M EBITDA)5.9x - 8.0x-6.7%
Transition (CHF 2M - 5M EBITDA)7.2x - 9.8x+11.1%
Lower Mid-Market (CHF 5M - 10M EBITDA)9.9x - 13.3x+33.3%
Mid-Market (> CHF 10M EBITDA)12.5x - 16.9x+66.7%

Source: NIMBO, Dealsuite, KPMG, SECA, Practitioner Interviews // Niche Baseline: 8.5x

Biotech & Contract Research Market in Zurich

Zurich — known for its role as a financial hub, high market liquidity — represents a significant market for Biotech & Contract Research companies in Switzerland. The local business environment is shaped by the canton's economic profile, offering distinct opportunities for both buyers and sellers in this niche.

Current EBITDA multiples for Biotech & Contract Research businesses range from 7.0 - 10.0x (statutory) to 9.0 - 14.0x (deal), reflecting a significant arbitrage opportunity. The sector trend is rising, driven by: Basel pharma ecosystem, highest multiples on platform, GLP/GMP regulatory moats, biologics pipeline demand. This positions Zurich as a notable market within the broader Life Sciences & Pharma sector.

ZurichEconomy Snapshot

Corporate Tax
19.7%
#20/26
Companies
92'500
99.1% SME
Unemployment
2.4%
Median Salary
CHF 7'280
/month
Succession Risk
31%
owners 55+

Why Biotech & Contract Research in Zurich?

Zurich offers a diversified economic base with 92'500 total companies. While not a primary hub for Biotech & Contract Research, the canton's competitive tax environment and skilled workforce create favorable conditions for business operations and valuations.

  • Switzerland's largest and most liquid financial centre with global banking, insurance, and asset management headquarters
  • Home to ETH Zürich and University of Zürich, generating world-class research talent and spin-offs
  • Zürich Airport provides unmatched international connectivity with over 200 direct destinations

Tax Impact on Valuation

At Zurich's effective corporate tax rate of 19.7% (rank #20/26), after-tax EBITDA retention is 80.3%. This directly influences enterprise valuations and buyer economics in the Biotech & Contract Research sector.

FAQ: Biotech & Contract Research in Zurich

How many Biotech & Contract Research companies are in Zurich?

Zurich has 92'500 total companies. Specific Biotech & Contract Research company counts are part of the broader industrial landscape.

What is the corporate tax rate in Zurich?

The effective corporate tax rate in Zurich is 19.7%, ranking #20 among Switzerland's 26 cantons.

What are Biotech & Contract Research valuation multiples in Zurich?

Current statutory EBITDA multiples for Biotech & Contract Research range from 7.0 - 10.0x. Deal-based multiples are 9.0 - 14.0x. These are influenced by Zurich's tax environment and local market conditions.

What is the business succession outlook in Zurich?

With over 12,000 SMEs led by owners aged 55+, Zürich faces the largest absolute succession challenge in Switzerland. The financial services, IT, and manufacturing sectors are particularly affected, creating significant M&A advisory demand.

Explore all industries in Zurich

Canton hub: tax data, industry composition, key employers

View Complete Biotech & Contract Research National Overview →

Full Swiss market analysis across all 26 cantons, including comparable M&A transactions and sector trends.